Damage-AMP (Alarmin Molecular Pattern) represents endogenous danger signals released from damaged, necrotic, or stressed cells that trigger sterile inflammation without pathogen presence. These include DAMPs such as HMGB1, heat shock proteins (HSP60, HSP70), extracellular ATP, uric acid crystals, S100 proteins, mitochondrial DNA (mtDNA), and cytochrome c. Damage-AMPs activate pattern recognition receptors (TLRs, NLRs, RAGE) on immune and tissue cells, initiating inflammatory cascades that mirror pathogen responses but originate purely from tissue injury.
Imagine a factory where all the machinery is designed to stay inside the building. The factory alarm system doesn't just respond to intruders (burglars = pathogens)—it also detects structural damage. When a wall collapses or a machine explodes (cell necrosis), internal components—wiring, coolant, blueprints, engine parts—spill out into the street where they don't belong. Passersby and security guards (immune cells) see these internal factory parts lying outside and immediately call emergency services, triggering the same alarm bells as if a burglar had broken in. The fire trucks and police (inflammatory cytokines) arrive either way. The key difference: if the factory had shut down properly with orderly demolition (apoptosis), everything would have been packed away neatly and no alarm would sound. But when the building explodes (necrosis or severe stress), the scattered internal debris itself becomes the alarm signal—not because it's foreign, but because it's in the wrong place at the wrong time. Chronic low-grade damage is like a factory constantly leaking coolant and dropping screws on the sidewalk: the alarms never fully stop, and the neighborhood stays on permanent alert.
Damage-AMPs are released through three primary mechanisms: necrotic cell death (uncontrolled membrane rupture), necroptosis (programmed necrosis), or active secretion under cellular stress (hypoxia, oxidative stress, mechanical trauma). Unlike apoptosis—where phosphatidylserine exposure and membrane integrity prevent DAMP release—necrotic cells lose plasma membrane integrity, releasing intracellular contents into extracellular space.
Key Damage-AMPs and their receptors:
-
HMGB1 (High Mobility Group Box 1):
- Normally a nuclear DNA-binding protein
- Released passively from necrotic cells or actively secreted by activated immune cells
- Binds TLR2, TLR4, TLR9, and RAGE (Receptor for Advanced Glycation End-products)
- HMGB1-TLR4 → MyD88 → IRAK1/4 → TRAF6 → TAK1 → IKK complex → NF-κB nuclear translocation → IL-1β, IL-6, TNF-α transcription
-
Extracellular ATP:
- Released from damaged mitochondria or stressed cells via pannexin channels
- Binds P2X7 receptor (ionotropic) and P2Y receptors (metabotropic)
- ATP-P2X7 → K+ efflux → NLRP3 inflammasome assembly → caspase-1 activation → IL-1β and IL-18 cleavage and release
- Rapidly degraded by ectonucleotidases (CD39, CD73) to adenosine (anti-inflammatory)
-
Uric acid crystals (monosodium urate):
- Final product of purine metabolism released during cell death
- Crystallizes at concentrations >6.8 mg/dL
- Phagocytosed by macrophages → lysosomal destabilization → cathepsin B release → NLRP3 inflammasome activation → IL-1β release
-
Heat Shock Proteins (HSP60, HSP70, HSP90):
- Intracellular chaperones exposed extracellularly during stress
- HSP60/70 bind TLR2 and TLR4 → NF-κB activation
- HSP70-TLR4 → CD14 co-receptor engagement → MyD88-dependent pathway
-
Mitochondrial DAMPs (mtDNA, N-formyl peptides, cytochrome c):
- Mitochondria retain bacterial ancestry; their components mimic PAMPs
- mtDNA contains unmethylated CpG motifs → TLR9 activation
- N-formyl peptides → formyl peptide receptor (FPR1) → neutrophil chemotaxis
- Cytochrome c released to cytoplasm → apoptosome formation (if apoptosis pathway active) or NLRP3 activation (if released extracellularly)
-
S100 proteins (S100A8/A9 = calprotectin):
- Calcium-binding proteins released from neutrophils and damaged epithelium
- S100A8/A9 dimers bind TLR4 and RAGE → NF-κB and MAPK activation
- Serum calprotectin >5 mg/L indicates active inflammation
Common downstream cascade:
graph TD
A[Necrotic Cell Death / Cellular Stress] --> B[DAMP Release]
B --> C[HMGB1]
B --> D[ATP]
B --> E[Uric Acid]
B --> F[HSPs]
B --> G[mtDNA]
C --> H[TLR4/RAGE]
D --> I[P2X7 Receptor]
E --> J[Phagocytosis]
F --> H
G --> K[TLR9]
H --> L[MyD88]
I --> M["K+ Efflux"]
J --> N[Lysosome Rupture]
K --> L
L --> O[IRAK1/4]
M --> P[NLRP3 Assembly]
N --> P
O --> Q[TRAF6]
P --> R[Caspase-1]
Q --> S[TAK1]
R --> T["IL-1β + IL-18 Release"]
S --> U[IKK Complex]
U --> V["NF-κB Activation"]
V --> W[Pro-inflammatory Cytokines]
W --> X["TNF-α, IL-6, IL-1β, CXCL1"]
T --> Y[Sterile Inflammation]
X --> Y
Critical distinction from apoptosis:
- Apoptosis = "immunologically silent" cell death: membrane integrity maintained → phosphatidylserine "eat me" signals → efferocytosis by macrophages → TGF-β and IL-10 (anti-inflammatory) release → no DAMP exposure
- Necrosis/Necroptosis = inflammatory cell death: membrane rupture → DAMP spillage → PRR activation → sterile inflammation
Threshold effects:
- Low-level chronic DAMP exposure → persistent low-grade inflammation (metaflammation)
- High-level acute DAMP release (trauma, ischemia-reperfusion) → cytokine storm, ARDS, multi-organ failure
- Exercise-induced muscle damage → transient DAMP release → hormetic adaptation if recovery adequate
Damage-AMPs are central to cPNI because they explain how non-infectious triggers produce inflammatory symptoms and disease progression. The AMP Metamodel positions Damage-AMP as one of 12+ categories of danger signals that converge on immune activation. Unlike Pathogen-AMP, Damage-AMPs represent sterile inflammation—the body attacking itself not because of infection, but because tissue integrity has been compromised.
Clinical contexts where Damage-AMPs dominate:
-
Metabolic syndrome and metaflammation:
- Adipocyte hypertrophy → mechanical stress → adipocyte death → HMGB1, free fatty acids, ceramides released → chronic low-grade inflammation
- Hepatocyte lipotoxicity (NAFLD/NASH) → ER stress → mitochondrial dysfunction → mtDNA and ATP release → Kupffer cell activation → liver fibrosis
- Elevated serum HMGB1 (>5 ng/mL) correlates with insulin resistance severity
-
Ischemia-reperfusion injury:
- Hypoxia → ATP depletion → membrane failure → massive DAMP release upon reperfusion
- Myocardial infarction, stroke, organ transplantation all feature DAMP-driven injury amplification
- Interventions: hypothermia, hyperbaric oxygen, antioxidants to reduce DAMP generation
-
Chronic pain syndromes:
- Persistent tissue damage (osteoarthritis, fibromyalgia) → continuous DAMP release → microglia and astrocyte activation → central sensitization
- Uric acid >7 mg/dL triggers gout attacks (NLRP3 activation)
- ATP signaling via P2X3 receptors on nociceptors → hyperalgesia
-
Wound healing paradox:
- Initial DAMP release is necessary for healing cascade (neutrophil recruitment, fibroblast activation)
- Chronic non-healing wounds (diabetes, venous ulcers) → persistent DAMP exposure → matrix metalloproteinases (MMPs) overexpression → collagen degradation exceeds synthesis
- Goal: support resolution mechanisms (SPMs, efferocytosis) to clear DAMPs after acute phase
-
Cancer progression:
- Tumor cell necrosis (chemotherapy, radiation, hypoxic core) → DAMP release → tumor-associated macrophage recruitment → angiogenesis, metastasis promotion
- HMGB1 in tumor microenvironment → TLR4 activation → NF-κB → VEGF, MMPs → tumor growth
- Paradox: immunogenic cell death (ICD) requires DAMP exposure for tumor antigen presentation but chronic DAMPs promote tumor escape
-
Exercise as hormetic Damage-AMP exposure:
- Eccentric exercise → Z-disc disruption → troponin, myoglobin, CK, LDH leak → transient inflammation
- If recovery adequate (48-72h) → adaptive hypertrophy, mitochondrial biogenesis
- If chronic overtraining → sustained DAMP elevation → immunosuppression, injury risk
Evolutionary mismatch perspective:
- Ancestral injury patterns: acute, resolved within days-weeks (fracture, laceration, infection)
- Modern chronic injury patterns: prolonged sitting (tissue compression ischemia), metabolic inflammation (lipotoxicity), psychological stress (cortisol-induced oxidative damage)
- Result: DAMPs designed for acute threat become chronic low-grade alarm signals
Intervention strategies in cPNI:
-
Reduce DAMP generation:
- Restore metabolic flexibility → reduce lipotoxicity and glucotoxicity
- Optimize sleep → reduce oxidative stress
- Movement variability → prevent chronic tissue compression/ischemia
- Antioxidants (vitamin C, E, polyphenols) during acute stress phases
-
Enhance DAMP clearance:
- Support efferocytosis: omega-3 fatty acids → resolvins → enhanced macrophage phagocytosis
- Autophagy induction: intermittent fasting, exercise → mitophagy → clear damaged mitochondria before rupture
- Hydration: uric acid crystallization prevented at adequate urine volume
-
Block DAMP receptors (pharmacological):
- TLR4 antagonists (experimental)
- Anti-HMGB1 antibodies (sepsis trials)
- IL-1 receptor antagonists (anakinra) for gout, autoinflammatory diseases
- P2X7 antagonists for neuropathic pain (investigational)
-
Promote resolution:
- SPM supplementation (resolvins, maresins, protectins) → terminate DAMP-driven inflammation
- Vagal tone enhancement → cholinergic anti-inflammatory pathway → reduced macrophage TNF-α response to DAMPs
Diagnostic markers:
- HMGB1: >5 ng/mL = active inflammation; >10 ng/mL = severe/systemic
- Calprotectin (S100A8/A9): fecal >50 μg/g = IBD activity; serum >5 mg/L = systemic inflammation
- Uric acid: >7 mg/dL men, >6 mg/dL women = hyperuricemia (gout risk)
- High-sensitivity CRP: >3 mg/L = chronic low-grade inflammation (often DAMP-mediated)
- Damage-AMPs trigger sterile inflammation—tissue injury without pathogen involvement—accounting for most chronic inflammatory diseases
- Necrotic cells release DAMPs; apoptotic cells remain immunologically silent due to maintained membrane integrity and phosphatidylserine exposure
- HMGB1 released from nuclei binds TLR2, TLR4, TLR9, and RAGE, making it one of the most promiscuous and potent DAMPs
- Extracellular ATP at micromolar concentrations activates P2X7 receptors, triggering NLRP3 inflammasome and IL-1β release within minutes
- Uric acid crystallizes at >6.8 mg/dL, activating NLRP3 inflammasome via lysosomal rupture pathway—the mechanism of gout attacks
- Mitochondrial DAMPs (mtDNA, N-formyl peptides) are uniquely inflammatory because mitochondria retain bacterial-like features from evolutionary endosymbiosis
- Serum calprotectin (S100A8/A9) >5 mg/L correlates with systemic inflammatory burden; fecal calprotectin >50 μg/g indicates active IBD
- Exercise-induced muscle damage releases CK (>200 U/L post-exercise), myoglobin, and HSPs transiently—hormetic if recovery window respected (48-72h)
- Chronic low-grade DAMP exposure (metaflammation) occurs at HMGB1 levels 2-5 ng/mL, below acute infection thresholds but sufficient for insulin resistance
- Ischemia-reperfusion injury features paradoxical DAMP surge upon oxygen restoration: ATP depletion → membrane failure → massive release upon reperfusion
- Tumor necrosis releases HMGB1 and ATP into microenvironment, recruiting tumor-associated macrophages that promote angiogenesis via VEGF and MMP secretion
- DAMPs activate same NF-κB pathways as PAMPs but resolve faster if efferocytosis and SPM production are intact
- damage-associated molecular patterns — Damage-AMP is the AMP category encompassing all DAMPs released from tissue injury, including HMGB1, ATP, uric acid, HSPs, and mtDNA
- HMGB1 — prototypical nuclear DAMP binding TLR2/4/9 and RAGE to trigger NF-κB and cytokine storm; serum >5 ng/mL indicates active inflammation
- ATP — extracellular ATP released from damaged mitochondria activates P2X7 receptor causing K+ efflux and NLRP3 inflammasome priming
- uric acid — purine degradation product crystallizing at >6.8 mg/dL, phagocytosed by macrophages to activate NLRP3 via lysosomal rupture
- heat shock proteins — HSP60/70/90 released during cellular stress bind TLR2/4, initiating MyD88-dependent inflammatory signaling
- mtDNA — mitochondrial DNA contains unmethylated CpG motifs activating TLR9; released during mitochondrial damage or necrosis as potent DAMP
- necrotic cells — uncontrolled cell death with membrane rupture releasing DAMPs, contrasting with immunologically silent apoptotic death
- TLR — Toll-like receptors 2, 4, and 9 recognize DAMPs (HMGB1, HSPs, mtDNA) triggering identical MyD88 pathway as pathogen PAMPs
- RAGE — Receptor for Advanced Glycation End-products binds HMGB1, AGEs, and S100 proteins, amplifying oxidative stress and NF-κB activation
- NF-κB — master transcription factor activated by DAMP-PRR signaling, driving TNF-α, IL-1β, IL-6, and CXCL1 production within 30-60 minutes
- NLRP3 inflammasome — intracellular sensor activated by ATP (P2X7), uric acid crystals (lysosomal rupture), and ROS, cleaving pro-IL-1β via caspase-1
- inflammation — Damage-AMPs trigger sterile inflammation without infection, explaining how metabolic stress, trauma, and ischemia produce inflammatory disease
- metaflammation — chronic low-grade metabolic inflammation driven by adipocyte death, hepatocyte lipotoxicity, and gut barrier damage releasing DAMPs
- Pathogen-AMP — parallel AMP category for microbial PAMPs (LPS, flagellin, dsRNA); DAMPs activate same PRRs but represent endogenous danger
- Lifestyle-AMP — sedentary behavior, chronic stress, and poor sleep increase oxidative damage and tissue injury, elevating Damage-AMP burden
- Emotional-AMP — chronic psychological stress increases cortisol-driven proteolysis and oxidative damage, releasing HMGB1 and mitochondrial DAMPs
- oxidative stress — ROS production damages mitochondria and cell membranes, triggering necrotic DAMP release; antioxidants reduce this cascade
- ischemia — hypoxia causes ATP depletion and membrane failure; reperfusion injury features massive DAMP surge (HMGB1, ATP, mtDNA) amplifying damage
- wound healing — initial DAMP release recruits neutrophils and activates fibroblasts for repair; persistent DAMPs prevent resolution and cause chronic wounds
- exercise — eccentric muscle damage releases CK, myoglobin, troponin, and HSPs transiently; hormetic adaptation requires 48-72h DAMP clearance window
- chronic pain — persistent tissue damage (arthritis, neuropathy) sustains DAMP release activating spinal microglia and dorsal horn neurons for central sensitization
- cancer — tumor necrosis releases HMGB1 recruiting tumor-associated macrophages; paradoxically promotes angiogenesis and metastasis via VEGF and MMPs
- COX-2 — induced by NF-κB activation downstream of DAMP signaling; produces PGE2 amplifying inflammation and pain unless acetylated by aspirin
- specialized pro-resolving mediators (SPMs) — resolvins, maresins, and protectins actively terminate DAMP-driven inflammation by enhancing efferocytosis and blocking NF-κB
- efferocytosis — macrophage phagocytosis of apoptotic cells and debris; when overwhelmed by necrotic DAMPs, efferocytosis fails and inflammation persists
- autophagy — cellular self-digestion process removing damaged mitochondria (mitophagy) before rupture, preventing mtDNA and cytochrome c DAMP release
- insulin resistance — chronic DAMP exposure (HMGB1, ceramides, free fatty acids) activates JNK and IKK, phosphorylating IRS-1 serine residues to block insulin signaling
- NAFLD — hepatocyte lipotoxicity triggers ER stress and mitochondrial dysfunction, releasing DAMPs that activate Kupffer cells driving steatohepatitis and fibrosis
- gout — monosodium urate crystals phagocytosed by synovial macrophages cause lysosomal rupture activating NLRP3 inflammasome for IL-1β release and acute arthritis
- fibromyalgia — central sensitization syndrome potentially driven by chronic low-grade DAMP exposure from micro-injuries, gut permeability, and mitochondrial dysfunction
- Alarmins — broader category of endogenous danger signals including DAMPs plus cytokines (IL-33, IL-1α) that signal tissue damage to immune system